Patent Picks are taken from publicly available sources. This edition features technologies related to skin care, topical delivery and more.
Zinc oxide complexes
US Patent 8404743
Publication date: March 26, 2013
Assignee: Mary Kay, Inc.
Described by this patent are compounds comprising a zinc oxide molecule chemically bound to one or more molecules having an acidic hydrogen, such as an organic acid. The compounds may be provided in topical skin formulations, pharmaceutical compositions or delivery systems for active ingredients. According to the inventors, this invention overcomes deficiencies in the art; while acidic molecules can be irritating to the skin, zinc oxide molecules can counteract this undesirable effect by providing a soothing quality to skin. Further, both the acidic molecule and the zinc oxide molecule can impart benefits to skin and produce a synergistic complex.
Antimicrobial compounds
WO/2013/040528
Publication date: March 21, 2013
Assignee: Microbiotix, Inc., ST Nguyen, X Ding, JD Williams and MM Butler
This invention discloses antimicrobial organic compounds and compositions thereof that kill or inhibit the growth of cells of one or more microbial pathogens. The method of application involves administration to an individual, or applied to or incorporated into a liquid, solid or semi-solid composition that is susceptible to or already contaminated with cells of one or more pathogenic microbial species. Compounds of the invention may also be used to treat solid surfaces, e.g., as a bacteriocide. Applciations include cosmetic products (including skin and hair care), foods, eye drops, contact lenses, ear drops, mouthwashes, toothpastes, dental appliances, nose drops, nose swabs and more.
Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
WIPO Patent Application WO/2013/040447
Publication date: March 21, 2013
Assignee: Medicis Pharmaceutical Corp., M Gold, J Cohen, G Munavalli and T-C Meng
This invention is directed to the use of complementary or combination photodynamic therapy and topical therapy with l-isobutyl-lH-im.idazo[4,5-c]-quinolin-4- amine, also known as l-(2-methylpropyl)-lH-imidazo[4,5-c]quinolin-4-amine or imiquimod, specifically to treat actinic keratosis. While the imiquimod topical therapy is generally administered first, followed by the photodynamic therapy with a non-treatment period in between, in some embodiments, the complementary, combination or follow-on therapies may be practiced in any sequential order.
System and method for treating skin and underlying tissues for improved health, function and/or appearance
WIPO Patent Application WO/2013/040443
Publication date: March 21, 2013
Assignee: Sigma Instruments Holdings, LLC, J Crunick, T Becse and LL Laskey, Jr.
Described here are systems and methods for treating facial soft tissues of a patient in a health care or cosmetic treatment environment, such as a spa, clinic or a medical practitioner's office. The treatment system includes a facial stimulator instrument and/or an acoustic oscillator to deliver therapeutic percussive massage, electrical stimulation and acoustic stimulation to the facial tissures. A facial treatment application executed on a computer processor identifies a treatment protocol and operates the facial stimulator instrument and/or acoustic oscillator to implement the treatment.
Herbal anti-aging skin care composition
WIPO Patent Application WO/2013/040395
Publication date: March 21, 2013
Assignee: Nefeli Corp.
Described here is a topical skin care composition containing an anti-aging extract solution of Dendrobium huoshanense and a carrier. Although a number anti-aging skin care products are commercially available, natural ingredients are often desired. Thus, this invention meets the needs of consumers seeking skin care products that are not only natural, but also effective; and with little or no side effects.
Novel surface markers for adipose tissues
WIPO Patent Application WO/2013/040391
Publication date: March 21, 2013
Assignee: Joslin Diabetes Center, Inc., RC Kahn and S Ussar
The present invention is basedon the discovery of brown and white fat cell-specific surface markers. It has been found that the small amino acid transporter Slca10/Asc1 is a specific surface marker for white adipocytes, and that the ligand-gated ion channel P2X5 and the small amino acid transporter Slc36a2 are specific surface markers for brown adipocytes. Having identified these specific white and brown cell surface markers, this invention provides compositions and methods suitable for the targeting of any number of agents to a white or brown adipose tissue.
Methods for administration and formulations for the treatment of regional adipose tissue
US Patent 8404750
Publication date: March 26, 2013
Assignee: Lithera, Inc.
Provided herein are pharmaceutical formulations, methods and systems for treating regional fat deposits and fat-related conditions and indications. Methods comprise administering a pharmaceutical formulation consisting essentially of a long-acting beta-2 adrenergic receptor agonist, for example, salmeterol, suitable for subcutaneous administration. Methods further comprise administering a pharmaceutical formulation that is suitable for subcutaneous injection comprising: a) a lipophilic long-acting selective beta-2 adrenergic receptor agonist and/or glucocorticosteroid, or a salt, optical isomer, racemate, solvate, or polymorph thereof; and b) at least one subcutaneously acceptable inactive ingredient.
Cyclodextrin-based polymers for therapeutics delivery
US Patent 8404662
Publication date: March 26, 2013
Assignee: Cerulean Pharma Inc., Insert Therapeutics Inc. and Calando Pharmaceuticals Inc.
Disclosed in this patent are novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic. Furthermore, by selecting from a variety of linker groups and targeting ligands, the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein.
